Trial Profile

Phase 2 Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) and Mantle Cell Lymphoma (MCL)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obinutuzumab (Primary) ; Venetoclax (Primary) ; Zanubrutinib (Primary)
Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
Focus Therapeutic Use

13 Mar 2025 Planned End Date changed from 1 Feb 2025 to 1 Feb 2026.
13 Mar 2025 Planned primary completion date changed from 1 Feb 2025 to 1 Feb 2026.
12 Dec 2023 Results (at data cut off May 15, 2023, n=25) assessing safety and efficacy of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naive, TP53-Mutant Mantle Cell Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com